Scientists probe how a natural substance fuels leukemia
NCT ID NCT04460963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines how adrenomedullin, a natural protein, affects leukemia stem cells in patients with acute myeloid leukemia (AML). Researchers will collect bone marrow and blood samples from 72 newly diagnosed AML patients to measure adrenomedullin levels and study its effects on cell growth and movement. The goal is to understand if blocking adrenomedullin could stop leukemia cells from multiplying, but this is a lab-based study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could point toward new ways to target leukemia stem cells by blocking adrenomedullin.
What could go wrong
This is an early, observational lab study with only 72 participants. It does not test a treatment in people, so any potential therapy is far off.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo
Bolzano, Italy
-
Ente Ecclesiastico Casa Sollievo Della Sofferenza - Ematologia
San Giovanni Rotondo, Italy
-
Policlinico S. Orsola-Malpighi - Uoc Ematologia
Bologna, Italy
-
U.O. Oncoematologia IOV
Castelfranco Veneto, Italy
-
Uo Ematologia - Azienda Ulss N.2 Marca Trevigiana
Treviso, Italy